contact@iebrain.com IN: +91-124-429-4218 US: +1-302-450-1418 UK: +44-770-014-9056
Healthcare research and global health technology assessment
Win the HTA Decision Before It Is Made

HTA Assessment

HTA evidence expectations differ by market and product type, and they keep evolving. Understand what each HTA body expects and close evidence gaps before reimbursement discussions begin.

Explore HTA capabilities ↓
Integrated HTA capabilities

End-to-end support for successful HTA decisions

We assist pharmaceutical, biotechnology, and medtech teams in understanding the expectations of each HTA body, in strengthening their evidence, and in filing their submissions with confidence.

HTA Landscape & Pathways

Health Technology Assessment (HTA) bodies do not evaluate products in the same way, and the requirements vary according to market, product type, and lifecycle stage. We analyse how each authority makes decisions so that you know which evidence, comparators, and timelines are relevant before you plan your submission.

Our services include:

  • Agency and assessment pathway mapping
  • Decision criteria, comparators, and timelines
  • Evidence expectations by market and product type
  • Global and local HTA roadmap

Evidence-Gap Assessment

Just because a trial gives positive results doesn't mean that you'll get a positive HTA outcome. We thoroughly review your clinical, economic, and real-world evidence in light of what the assessors expect and recognize any gaps or uncertainties that could weaken your case while there's still time to deal with them.

Our services include:

  • Clinical and economic evidence review
  • Comparator and endpoint alignment check
  • Uncertainty and risk identification
  • Evidence-generation recommendations

Clinical & Economic Evidence Synthesis

Assessors require evidence that is relevant, transparent, and reproducible. We combine data from trials, real-world sources, and the existing literature into a coherent evidence base and develop the economic models that demonstrate whether your price is justified by the benefits to patients.

Our services include:

  • Systematic and targeted literature reviews
  • Indirect treatment comparisons
  • Cost-effectiveness modeling
  • Budget impact modeling

HTA Dossier Development

A dossier must meet agency requirements and still tell a clear value story. Since we carry out our work as a single team in the areas of evidence, economics, and scientific writing, your submission is coherent and addresses the kinds of questions that assessors are likely to ask.

Our services include:

  • Agency-specific dossier development
  • Value narrative and key messaging
  • Adaptation across global and local submissions
  • Pre-submission quality review

Payer & HTA Stakeholder Intelligence

The recommendations of HTA and the decisions of payers are influenced by precedent, policy, and stakeholder priorities. By gathering insights into how decision-makers have evaluated similar products and what they consider important, your evidence and engagement strategies can take this into account.

Our services include:

  • Payer and HTA stakeholder insights
  • Reimbursement precedent analysis
  • Value expectations by market
  • Inputs for payer engagement strategy

Post-HTA Decision Monitoring

The work doesn't conclude with a submission. Reviewers may raise questions, impose conditions, or give a negative recommendation. We keep a record of the outcomes and any policy changes and will assist you in your response, so that you can safeguard and enhance access afterwards.

Our services include:

  • HTA decision and policy tracking
  • Clarification and additional analysis support
  • Resubmission and appeal strategy
  • Access and reimbursement recommendations
Healthcare research supporting health technology assessment
Evidence That Counts

HTA bodies judge more than clinical results

HTA bodies ask harder questions than "does it work?" They want relevant comparators, reliable evidence synthesis, transparent economic models, and outcomes that matter to patients. Where the data is uncertain, they want that explained, not hidden.

We bring scientific research, health economics, market access insight, and strategic communication together in one team. The evidence package that reaches assessors reads as one consistent story in every market you submit to.

Our Approach

Four Moves That Decide An HTA Outcome …

HTA bodies rarely reject a product for lack of data. They reject it for the wrong comparator, weak long-term evidence, or a price the model cannot defend. We plan around those risks from day one.

Read the Assessor

Each agency has its own comparators, endpoints, and cost-effectiveness thresholds. We map them for your product before you commit to an evidence plan.

Stress-Test the Evidence

Immature survival data, missing comparators, and thin real-world evidence get flagged early, while there is still time to fix them.

Build a Case That Holds

Indirect comparisons and economic models that stand up to scrutiny, tied together in one value story.

Defend the Decision

Clarification questions, hearings, and negotiations handled with the same team that built the dossier, with resubmission or appeal ready if needed.

What Sets Us Apart?

Integrated Evidence, Economics, and Scientific Reviews

Indirect comparisons, literature reviews and economic models – all handled by our collaborated team of experts, keeping data, assumptions, and messaging consistent across the submission.

Early Identification of Evidence Gaps

Clinical, economic, and real-world evidence reviewed against assessor expectations before submission, so gaps can be addressed while options remain open.

Coordinated Global and Local Submissions

A common evidence base adapted to the requirements of each market, avoiding duplication across submissions.

Payer and HTA Precedent Analysis

Structured analysis of HTA recommendations and payer decisions for comparable products, translated into evidence priorities and market-specific positioning.

Continuity After Submission

Offer extended support with clarification questions, additional analyses, conditional recommendations, resubmissions, and appeals, delivered by the team that developed the dossier.

Expert-led Delivery

A team of 20+ professionals, including PhD holders and domain experts, with deep HTA and market access knowledge.

Preparing for an HTA Submission or Reimbursement Decision?

Identify evidence gaps, prioritize your needs across target markets, and build a clear strategy for your next assessment.

Latest perspectives

HTA insights

Practical thinking on assessment readiness, comparative evidence, economic evaluation, submission strategy, and reimbursement.

Inflammatory bowel disease illustration
Case Study

Winning the Reimbursement Race Before It Starts: How We Helped a Global Biopharma Leader Build Competitive Resilience in IBD

Learn how we turned fragmented HTA and payer intelligence into market-by-market priorities, helping a global biopharma leader get ahead of reimbursement risk in IBD before competitor launches.

Healthcare research and global evidence strategy
Featured Insight

Building a Global Evidence Strategy for Overseas Reimbursement Success

Discover how pharma companies bridge the gap from regulatory approval to global reimbursement with an integrated evidence strategy built from day one.

Joint Clinical Assessment dossier and European map
Featured Insight

One Clinical Dossier, 27 Member States: How the EU Joint Clinical Assessment Is Changing Drug Launches?

Learn how one assessment across 27 markets is influencing drug launch strategies across the EU.

Start a conversation

Don't let one evidence gap decide your HTA outcome

Tell us your target market, submission stage, or evidence gap. We will come back with a clear view of what the assessor will look for and where to focus first.

Thank you. Your request has been received.

HTA services help pharmaceutical, biotechnology, and medtech companies prepare for evaluations by HTA bodies. Our services include assessment pathway mapping, evidence-gap assessment, evidence synthesis, economic modeling, dossier development, and post-decision support. These assist you in demonstrating the clinical and economic value of your product.

HTA bodies assess clinical benefit, comparator relevance, evidence quality, patient-relevant outcomes, and cost-effectiveness. Expectations vary by country, product type, and life cycle, so the evidence plan must be tailored to reflect the priorities set by each HTA agency.

The ideal time to prepare for the assessment is during the clinical trial or pre-launch planning phase. Early engagement allows you to align trial design, comparators, and endpoints with assessor expectations, and identifies evidence gaps while there is still time to address them.

It is a structured review of a product's clinical, economic, and real-world evidence against the requirements of target HTA bodies. It highlights the key uncertainties, evidence gaps, and the necessary research to generate to improve your submission.

Each HTA body has unique assessment criteria, including different evidence requirements, head-to-head comparators, and timelines. We perform a cross-market analysis and build a global/local assessment pathway to help you establish an evidence-generating strategy that meets the needs of every market.

An HTA dossier typically includes clinical evidence, comparative effectiveness, economic models, such as cost-effectiveness and budget impact, and a value narrative. The exact content and format depend on the requirements of each agency.

Collaborative delivery

Built for cross-functional market access teams

“

An early HTA strategy helps clinical, medical, health economics, and access teams align before evidence gaps become submission risks.

HS
HTA Strategy Readiness planning
“

Transparent assumptions and well-documented methods make economic evidence easier for assessors to review and challenge.

EE
Economic Evaluation Decision modelling
“

A consistent value story connects comparative benefit, patient need, affordability, and uncertainty across every submission component.

VC
Value Communication Submission clarity

Copyright © 2026 Ingenious e-Brain

Contact Us